Clinical trials: Endometrial Cancer, open to volunteers
Endometrial Cancer Stage III, Endometrial Cancer Stage IV
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
- Conditions
- Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent
- Trial name
- PROMOTE (NCT03621904)
- Testing
- Hormonal Antineoplastics
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Endometrial Cancer, Adjuvant Radiotherapy
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
The purpose of this study is to compare the efficacy and toxicity of early stage endometrial cancer based on molecular classification and conventional risk stratification adjuvant therapy decision-making, and to provide…
- Conditions
- Endometrial Cancer, Adjuvant Radiotherapy, Molecular Classification
- Trial name
- NCT05524389
- Testing
- Vaginal brachytherapy, Pelvic external beam radiotherapy, Observation
- Volunteers
- 624 people
- Sponsor
- Peking Union Medical College Hospital
Endometrial Cancer
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Patients with advanced mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) endometrial cancer (EC) are currently treated as one entity, and immune checkpoint inhibitor (ICI) monotherapy is the treatment of…
- Trial name
- CAN-RESPOND (NCT05550558)
- Testing
- Anlotinib + Camrelizumab
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Endometrial Cancer, Cervical Cancer
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined.
- Conditions
- Endometrial Cancer, Cervical Cancer, Sentinel Lymph Node, Micrometastasis
- Trial name
- ITCMicroUtCa (NCT04403867)
- Testing
- Sentinel lymph node (SLN) biosy +/- lymphadenectomy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Endometrial Cancer
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Aim to compare chemotherapy alone or chemoradiotherapy for post-operative endometrial cancer (stage I-IVA) with p53 mutation.
- Trial name
- NCT05489848
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Volunteers
- 294 people
- Sponsor
- Fudan University
Endometrial Cancer
Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer
Through this clinical trial, the investigators aim to verify the usefulness and stability of sentinel lymph node mapping in endometrial cancer of clinical stage I-II.
- Trial name
- SELYE (NCT04845828)
- Testing
- Sentinel lymph node mapping, Routine lymph node dissection
- Where
- South Korea
- Volunteers
- 810 people
- Sponsor
- Asan Medical Center
Brachytherapy, Uterine Cervical Neoplasms
Retrospective Study of Brachytherapy
Brachytherapy for gynecological cancers will be studied retrospectively.
- Conditions
- Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer
- Trial name
- RetroBT (NCT05242861)
- Testing
- Brachytherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Endometrial Hyperplasia, Endometrial Cancer
Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia
This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to anti-hormone therapy.
- Conditions
- Endometrial Hyperplasia, Endometrial Cancer, Gynecologic Cancer
- Trial name
- FETCH (NCT04362046)
- Testing
- Hysteroscopic uterine resection
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Vancouver Coastal Health Research Institute
Endometrial Cancer, Atypical Endometrial Hyperplasia
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early…
- Trial name
- NCT03463252
- Testing
- Progesterone, Mirena®, GnRH agonist
- Where
- China
- Volunteers
- 224 people
- Sponsor
- West China Second University Hospital
Cancer, Breast Cancer
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion.
- Conditions
- Cancer, Breast Cancer, Gastric Cancer, Renal Cancer
- Trial name
- ONCOPRO (NCT03787056)
- Testing
- Blood draws
- Where
- 17 sites in France
- Volunteers
- 410 people
- Sponsor
- Hospices Civils de Lyon
Endometrial Cancer, Pathology
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.
- Conditions
- Endometrial Cancer, Pathology, Radiotherapy
- Trial name
- NCT04956601
- Testing
- vaginal brachytherapy/pelvic external beam radiotherapy
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Peking University Third Hospital
Endometrial Cancer
European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III
Intermediate/high risk endometrial cancer shows locoregional recurrence rates up to 20%. Also in so called low-risk disease 5-10% incidence of nodal metastasis is reported.
- Trial name
- PMMR (NCT04504006)
- Testing
- Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Dr. Paul Buderath
Endometrial Cancer
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer
Endometrial cancer is the most common gynecological malignancy affecting women's health. About 15% of the patients will have local late disease (stage III) with high risk of recurrence and tumor related mortality.
- Trial name
- NCT04453904
- Testing
- sequential radiochemotherapy in a "sanwich" mode
- Where
- China
- Volunteers
- 654 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer
3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer
To verify the safety of omission of lymph node dissection in ultra-low-risk endometrial cancer (KGOG criteria), we examine the survival of women with ultra-low-risk endometrial cancer who do not undergo lymph node dissection
- Trial name
- TREE PRO (NCT04227249)
- Testing
- no lymph node dissection
- Volunteers
- 153 people
- Sponsor
- Seoul National University Hospital
Endometrial Cancer
Biomarker Guided Treatment in Gynaecological Cancer
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer.
- Trial name
- Momatec2 (NCT02543710)
- Testing
- Biomarker (ER/PR) guided lymphadenectomy, Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
- Where
- 9 sites in Netherlands, Norway and 1 more
- Volunteers
- 1,300 people
- Sponsor
- Haukeland University Hospital